Tiziana Life Sciences Ltd TLSA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -96.14% | -76.56% | -55.37% | -22.20% | 6.46% |
| Total Depreciation and Amortization | 102.67% | 96.35% | 88.71% | 69.16% | 45.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.88% | -64.02% | -78.75% | -33.12% | 77.78% |
| Change in Net Operating Assets | 280.14% | 326.25% | 654.71% | -118.36% | -174.33% |
| Cash from Operations | -52.93% | -155.25% | -741.87% | -297.57% | -123.99% |
| Capital Expenditure | -581.82% | -220.00% | -10.53% | 3.03% | 21.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -93.83% | 12.34% | -- | 695.00% | 388.60% |
| Cash from Investing | -96.42% | 10.15% | 16,115.79% | 672.89% | 383.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -131.67% | -81.61% | -39.01% | -8.22% | 20.53% |
| Issuance of Common Stock | -22.13% | 17.01% | 118.55% | 375.44% | 48,116.00% |
| Repurchase of Common Stock | -- | -- | -- | 0.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -64.44% | -- |
| Cash from Financing | -22.93% | 17.31% | 124.70% | 390.54% | 131,922.22% |
| Foreign Exchange rate Adjustments | -58.41% | 151.57% | 122.89% | 121.34% | 120.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -166.54% | -143.72% | -88.74% | 318.97% | 211.96% |